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Introduction
Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare inflammatory disorder that primarily affects children.
Its hallmark is recurring episodes of sterile osteomyelitis.
The clinical presentation is insidious bone pain with or
without fever. Pathogenesis is still unknown and there is
no any effective treatment.
Objectives
The aim of our study is to describe our experience with
CRMO over the past ten years.
Methods
We retrospectively evaluated patients with CRMO who
had been diagnosed at or referred to Rheumatology Service
of Institute for Maternal and Child Health - IRCCS Burlo
Garofolo -between 2004 and 2014. History, diagnostic
imaging, laboratory and histological data were obtained.
Results
We followed seven patients diagnosed as CRMO, 6 female
and 1 male. Bone pain was the leading symptom; median
age of first complaint was 11 years (range 8-14 ys). The
majority of bone lesions were located in the metaphyses of
the long bones (10 sites, 63%), clavicle (3 sites, 19%) and
pelvis (2 sites, 12%). Five patients had more than one
lesion at onset. Of the latter, one patient remained with
only one bone focus. Bilateral involvement was presented
in two cases. The male patient also had fever and severe
acne, so received diagnosis of SAPHO (synovitis, acne,
pustulosis, hyperostosis, and osteitis) syndrome. Blood
examination revealed slight increased eritrosedimentation
rate and normal C-reactive protein in all cases. In two
cases, at any disease relapse, urine analysis revealed protei-
nuria without other signs of renal involvement. One
patient underwent renal biopsy that showed a mesangial
glomerulonephritis. In all patients X-rays were suggestive
of osteomyelitis. In all patients diagnosis was formalized
after biopsy, except for patient with SAPHO. The biopsy
showed scattered inflammatory infiltrate and leukocytes
with no evidence of bacteria or malignancies in any cases.
No patients responded to non-steroidal anti-inflammatory
drugs (NSAIDs) therapy. All patients received corticoster-
oids but only two of them reached clinical remission. Of
the remaining, one received methotrexate and then inflixi-
mab with no benefit so switched to bisphosphonate with
partial response and 3 received bisphosphonate with good
clinical response. The patient with SAPHO received Inflix-
imab with good response. After 4 years, patient with
SAPHO is still on infliximab therapy as an attempt of
withdrawal provoked a flare of the disease. Four patients
are clinically asymptomatic with no therapy, one patient is
on bisphosphonate therapy, and one patient showed recur-
rent course despite biphosphonate and biological anti-
TNFa therapy.
Conclusion
The clinical course of CRMO is variable. The metaphyses
of the long bones remain the more affected sites followed
by clavicle and pelvis. Laboratory tests are aspecific and
the biopsy is necessary, especially in cases with singular
localization. In two patients we also found intermittent
proteinuria, that has never been reported so far. In our
opinion two hypothesis could be considered: proteinuria is
a sign of renal involvement in some cases of CRMO, orUniversity of Trieste, Institute for Maternal and Child Health IRCCS BurloGarofolo , Trieste, Italy
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proteinuria is a side effect of treatment. In fact in one
patient when infliximab was withdrawn, proteinuria
permanently disappeared. Bisphosphonate therapy can be
of benefit to patients with relapsing symptoms. In refrac-
tory patients biologic therapy could be considered even if
no controlled studies are disposable.
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